Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study provided the first published case reports of alopecia associated with the use of quetiapine.

The authors report a dementia patient who developed severe trichotillomania unresponsive to SSRIs, which improved with quetiapine; they suggest dopamine blockade may manage such symptoms in dementia.

This review found that patients taking antiandrogens, 5 alpha-reductase inhibitors, and spironolactone have an increased risk of developing gynecomastia, potentially due to hormonal changes.

This report describes the first known case of alopecia in a 16-year-old patient associated with quetiapine use, which resolved after stopping the medication.

This case report details a 28-year-old male who developed trichotillomania following a traumatic brain injury, highlighting diagnostic challenges in distinguishing overlapping psychiatric and compulsive behaviors, and underscores the importance of a comprehensive, multidisciplinary treatment approach.

In this study, a 37-year-old Moroccan man experienced hair loss after two months of quetiapine treatment for major depressive disorder, which resolved after discontinuation, highlighting the need for awareness of this potential rare side effect.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.

This review discusses the challenges of diagnosing and treating pediatric bipolar disorder and highlights the potential benefits of combined psychopharmacological treatments, noting no long-term efficacy from mood stabilizer monotherapy.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

Monitoring for adverse effects in clinical treatments is crucial.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.

This case study reports instances of hair loss in two patients taking sertraline, suggesting that even low doses of SSRIs might cause this rare side effect, which could impact treatment adherence.

This report describes five cases where sudden akathisia occurred in female patients with bipolar disorder after a ziprasidone dose reduction, emphasizing potential unexpected side effects of second-generation antipsychotics.

This study presents two case reports where patients experienced hair loss during treatment with the SSRI sertraline, highlighting this rare but potential side effect.

This case study documents a potential relationship between venlafaxine use and the onset of paranoia, which resolved upon discontinuation and recurred when reintroduced.

This case report describes a 21-year-old male who experienced sertraline-induced diffuse hair loss that improved after discontinuing the medication.

This case report from the University of Alabama describes a rare paradoxical effect where divalproex sodium was associated with increased agitation and hostility in a patient with schizoaffective disorder.

This case report from the University of Alabama, Birmingham describes a rare paradoxical reaction of increased agitation and hyperactivity in a patient with schizoaffective disorder treated with divalproex sodium.

This case report suggests that Citalopram may cause reversible hair loss in some patients, as evidenced by hair regrowth after discontinuing the drug.

This case report suggests that long-acting injectable risperidone may induce hirsutism in some patients, and clinicians should monitor for this potential side effect when prescribing this antipsychotic.

This study found that videoconferencing enabled reliable and consistent assessment of negative symptoms in patients with schizophrenia, demonstrating high interrater reliability among blinded independent raters.

This case report describes reversible hair loss in a patient taking aripiprazole, suggesting this side effect may be common among psychotropic medications.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This review discusses the potential for SSRIs to cause serious skin reactions and suggests considering alternative antidepressants if such reactions occur.

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

This report describes a case of significant hair loss in a 51-year-old woman treated with paroxetine, which improved after stopping the medication, highlighting the complex nature of drug-associated alopecia.

Increasing olanzapine caused hair loss in a woman, which stopped after changing medication.